Insider Buying: Aralez Pharmaceuticals Inc. (ARLZ) Director Purchases $73,500.00 in Stock

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) Director Arthur S. Kirsch acquired 50,000 shares of Aralez Pharmaceuticals stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average cost of $1.47 per share, for a total transaction of $73,500.00. Following the purchase, the director now owns 271,609 shares of the company’s stock, valued at $399,265.23. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Aralez Pharmaceuticals Inc. (NASDAQ ARLZ) traded down $0.03 during trading on Friday, hitting $1.41. 468,900 shares of the company traded hands, compared to its average volume of 848,217. The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64. Aralez Pharmaceuticals Inc. has a one year low of $0.95 and a one year high of $5.05.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The company had revenue of $24.30 million for the quarter, compared to analysts’ expectations of $22.87 million. During the same quarter in the previous year, the firm posted ($0.32) earnings per share. Aralez Pharmaceuticals’s revenue for the quarter was up 78.7% on a year-over-year basis. sell-side analysts predict that Aralez Pharmaceuticals Inc. will post -1.54 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of the stock. GSA Capital Partners LLP grew its stake in shares of Aralez Pharmaceuticals by 88.5% in the second quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock worth $731,000 after purchasing an additional 254,400 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Aralez Pharmaceuticals by 71.3% in the third quarter. Wells Fargo & Company MN now owns 273,130 shares of the company’s stock valued at $625,000 after buying an additional 113,720 shares during the period. Intrinsic Edge Capital Management LLC acquired a new position in Aralez Pharmaceuticals in the second quarter valued at $270,000. Brown Advisory Securities LLC acquired a new position in Aralez Pharmaceuticals in the third quarter valued at $394,000. Finally, Isthmus Partners LLC lifted its holdings in Aralez Pharmaceuticals by 0.8% in the second quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock valued at $208,000 after buying an additional 1,285 shares during the period. 19.60% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Insider Buying and Selling by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply